Geron Corp (GERN)

[prime3end]

Big thing is selecting cancer types for each trial that are easiest to determine the drugs effectiveness. For other drugs that have a cancer specific target that other cancers don't have, or express to a varying degree, you have to spend a lot of money on imaging etc ,, to see how well the drug is doing. So as far as expensing, for the most part Geron is able to keep the costs low by selecting cancers that are easy to get good indications on, like prostate in the phase 1/2 vaccine trial, and like CLL for the GRN163 phase 1/2. The all comers, all tumore types trial at U of Chicago might be different, I don't know but its possible that the hospital or patients insurance is going to pay for some of the imaging? , etc, anyway. I'd like to know that and like to be reminded how many will be in the trial.